

Grifols breaks ground on new manufacturing site in Spain

- *Grifols plans to invest EUR 160 million in the initial phase of the new facility, which will increase the company's plasma fractionation capacity by three million liters annually to meet the needs of more than 300,000 patients across Europe who rely on plasma-derived therapies*
- *The new facilities in Lliçà de Vall (Barcelona), expected to begin operations in 2030, will join Grifols' complex in Parets del Vallès (Barcelona) to create a 25-hectare biotechnology hub with more than 3,700 employees, including 400 newly created jobs*
- *The plant, designed as a highly digitalized smart factory, will operate using 100% renewable electricity and incorporate advanced energy- and resource-management systems*
- *The groundbreaking event was attended by the President of the Government of Spain, Pedro Sánchez, who highlighted the strategic importance of the project*

Barcelona, June 3, 2026 – Grifols (MCE:GRF, MCE:GRF.P, NASDAQ:GRFS), a global healthcare company and leader in the production of plasma-derived medicines, today held the groundbreaking ceremony for its new plant in Lliçà de Vall (Barcelona). The facility, expected to begin operations in 2030, will strengthen the company's industrial capacity in Catalonia to meet the growing demand for plasma-derived medicines in Europe.

The event was attended by the President of the Government of Spain, Pedro Sánchez; the Minister of Industry and Trade of the Spanish government, Jordi Hereu; the Minister for Research and Universities of the Government of Catalonia, Núria Montserrat; the Secretary of State and Director of the Office for Economic Affairs and the G20, Manuel de la Rocha; the Mayor of Lliçà de Vall, Xavier Castillejo; among other authorities, as well as the Vice Chairman of the Grifols Board of Directors, Raimon Grifols, and Board members Víctor Grifols Deu, Albert Grifols Coma-Cros and Tomás Dagá.

In his remarks, Pedro Sánchez highlighted that “this new facility represents a major step forward for Grifols and will help strengthen Europe’s strategic autonomy in the healthcare, industrial, and technology sectors.” He added, “We will continue to support the pharmaceutical and biotechnology industries, which are so important to Catalonia and Spain.”

Xavier Castillejo, Mayor of Lliçà de Vall, stated that “the facility will contribute to the development of the Vallès Oriental region and create opportunities for people and future generations.”

Raimon Grifols said, “The laying of this foundation stone symbolizes Grifols’ commitment to continued growth rooted in the region, with an industrial vision focused on serving patients. This new plant will enable us to expand our production capacity for plasma-derived medicines in Europe and contribute to strengthening the continent’s strategic autonomy and self-sufficiency. From Vallès Oriental, where we have carried out industrial activity for more than five decades, we continue to build the future with a commitment to ensuring that more patients can access essential therapies.”

The plant represents an initial investment of EUR 160 million. Once completed, it will increase Grifols' plasma fractionation capacity in Europe by three million liters, further strengthening the company's ability to ensure the supply of essential medicines, such as immunoglobulins and other plasma-derived treatments, for the more than 300,000 patients across the continent.

The new facilities in Lliçà de Vall will join Grifols' complex in Parets del Vallès (Barcelona) to form a 25-hectare biotechnology hub with more than 3,700 employees, including 400 newly created jobs.

The center will include a plasma fractionation plant, logistics operations, a testing laboratory and warehouses. It will also feature a new space for Grifols Engineering, which - recognized globally for designing world-class biopharmaceutical facilities - will design and construct the Lliçà de Vall expansion.

A strategic project based on a highly digitalized, sustainable smart factory model

The Lliçà de Vall expansion has been designated a strategic project by the Government of Catalonia. Conceived as a next-generation facility based on a smart factory model, it will leverage digitalization and advanced data systems to optimize production, enhance operational efficiency, reduce energy and water consumption and minimize waste compared to conventional facilities.

As a global leader in environmental sustainability, Grifols integrates energy efficiency, digitalization and circular-economy principles into the design of its industrial facilities with the aim of minimizing its environmental impact and advancing toward a responsible, long-term growth model.

The company expects the new plant to operate using 100% renewable electricity and is exploring the integration of a biogas facility capable of supplying up to 30% of its natural gas needs. This builds on the experience of the Parets del Vallès complex, where Grifols operates an anaerobic treatment plant that has reduced organic pollutant load by 85% and generates renewable biogas used as fuel in the production process.

The campus will also incorporate intelligent resource-monitoring and management systems to optimize energy and water use. Through these measures, Grifols aims to improve energy efficiency by 15%, reduce emissions by 60% and achieve approximately 20% water savings - reinforcing its commitment to a responsible energy transition that exceeds regulatory requirements.

The project integrates circular-economy best practices, enabling the reuse, recycling, repair and repurposing of materials throughout their life cycles. The planned biogas facility would further support this approach by generating renewable energy from industrial by-products.

The investment in Lliçà de Vall reflects Grifols' longstanding commitment to generating economic and social value in the regions where it operates. In Spain, Grifols currently employs more than 4,700 people and supports over 16,000 indirect jobs - contributing an estimated more than EUR 1.5 billion to the national economy.

About Grifols

Grifols is a global healthcare company founded in Barcelona in 1909 committed to improving the health and well-being of people around the world. A leader in essential plasma-derived medicines and transfusion medicine, the company develops, produces and provides innovative healthcare services and solutions in more than 110 countries.

Patient needs and Grifols' ever-growing knowledge of many chronic, rare and prevalent conditions, at times life-threatening, drive the company's innovation in both plasma and other biopharmaceuticals to enhance quality of life. Grifols focuses on treating conditions centered on six core therapeutic areas: immunology, neurology, pulmonology, hematology, hepatology and intensive care.

A pioneer in the plasma industry, Grifols continues to grow its network of donation centers, the world's most diversified with more than 400 across North America, Europe, Africa and the Middle East, and China.

As a recognized leader in transfusion medicine, Grifols offers a comprehensive portfolio of solutions designed to enhance safety from donation to transfusion, in addition to clinical diagnostic technologies. It provides high-quality biological supplies for life-science research, clinical trials and for manufacturing pharmaceutical and diagnostic products. The company also supplies tools, information and services that enable hospitals, pharmacies and healthcare professionals to efficiently deliver expert medical care.

Grifols, with more than 25,000 employees in more than 30 countries and regions, is committed to a sustainable business model that sets the standard for continuous innovation, quality, safety and ethical leadership.

The company's class A shares are listed on the Spanish Stock Exchange, where they are part of the IBEX-35 (MCE:GRF). Grifols non-voting class B shares are listed on the Mercado Continuo (MCE:GRF.P) and on the U.S. NASDAQ through ADRs (NASDAQ:GRFS).

For more information about Grifols, please visit www.grifols.com

MEDIA CONTACTS:

Grifols Press Office

media@grifols.com

Phone: +34 93 571 00 02

INVESTORS

Investors Relations & Sustainability

inversores@grifols.com - investors@grifols.com

sostenibilidad@grifols.com - sustainability@grifols.com

Phone: +34 93 571 02 21

LEGAL DISCLAIMER

The facts and figures contained in this report that do not refer to historical data are 'projections and future hypotheses'. Words and expressions such as 'believe', 'expect', 'anticipate', 'predict', 'hope', 'intend', 'should', 'will try to achieve', 'is estimated', 'future' and similar expressions, insofar as they refer to the Grifols group, are used to identify future projections and hypotheses. These expressions reflect the assumptions, hypotheses, expectations and predictions of the management team at the time of writing this report, and these are subject to a series of factors that mean that the real results may be materially different. The future results of the Grifols group could be affected by events related to its own activities, such as shortages of supplies of raw materials for the manufacture of its products, the appearance on the market of competing products, or changes in the regulatory framework of the markets in which it operates, among others. At the date of preparation of this report, the Grifols group has adopted the necessary measures to mitigate the foreseeable impact of these events. Grifols, S.A. assumes no obligation to publicly report, revise or update the projections or future hypotheses to adapt them to facts or circumstances after the date of writing of this report, except when expressly required by applicable legislation. This document does not constitute an offer or invitation to purchase or subscribe shares in accordance with the provisions of Law 6/2023, of 17 March, on the Securities Markets and Investment Services, and any regulations implementing said legislation. Furthermore, this document does not constitute an offer to purchase, sell or exchange, or a solicitation of an offer to purchase, sell or exchange any securities, or a solicitation of any vote or approval in any other jurisdiction. The information contained in this document has not been verified or revised by the external auditors of the Grifols group.